Tumor glycolytic profiling through (18)F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC

BACKGROUND: A significant proportion of patients with non-small-cell lung cancer (NSCLC) do not respond to immune checkpoint inhibitors (ICIs). Since metabolic reprogramming with increased glycolysis is a hallmark of cancer and is involved in immune evasion, we used (18)F-fluorodeoxyglucose positron...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, Saulo Brito, Wanderley, Carlos Wagner S., Gomes Marin, José Flavio, de Macedo, Mariana Petaccia, do Nascimento, Ellen Caroline Toledo, Antonacio, Fernanda Frozoni, Figueiredo, Caroline Sales, Trinconi Cunha, Mateus, Cunha, Fernando Q., de Castro Junior, Gilberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730014/
https://www.ncbi.nlm.nih.gov/pubmed/36506107
http://dx.doi.org/10.1177/17588359221138386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730014/
https://www.ncbi.nlm.nih.gov/pubmed/36506107
http://dx.doi.org/10.1177/17588359221138386

Ejemplares similares